Qualiveen was developed as a disease specific quality of life measure for individuals with SCI who have urinary disorders that could be used in international multi-centre trials (Costa et al. 2001). The tool was developed by a multi-disciplinary group of experts and the questions were derived based on the literature and individuals with SCI.  There are four scales: limitations, constraints, fears, and feelings.

Number of items: 30

Procedure/Administration: The Qualiveen can be administered by interviewer or be self-administered.  The questionnaire is based on a 5 point Likert scale. 

How scored: No details provided.

Interpretability: Each of the four scales are scored from 0 - 100, where lower scores indicate a better quality of life (i.e. no limitations, fears, constraints, or negative feelings) and higher scores indicate a poorer quality of life.  Data is only provided from one study, so no normative data exists.

Acceptability: The Qualiveen was developed specifically for individuals with SCI and was developed with input from individuals with SCI. 

Languages: English and French

Usability: N/a

Time to administer: N/a

Time to score: N/a

Training required: N/a

Availability: N/a

Equipment required: N/a

Summary: N/a

Psychometric Summary:

Note: TR= Test re-test; IC= Internal Consistency; Inter-O= Inter-observer; Intra-O= Intra-observer; SS= Sensitivity/Specificity; N/a= No information.

Red light= A single study involving SCI subjects which has less than adequate findings of reliability, validity, and/or responsiveness.

Yellow light= A single study involving subjects with SCI which has adequate to excellent findings of reliability, validity, and/or responsiveness.

Green light= At least 2 studies involving subjects with SCI which have adequate to excellent findings of reliability, validity, and/or responsiveness.

References

• Costa P, Perrouin-Verbe B, Colvez A, Didier J, Marquis P, Marrel A, Amarenco G, Espirac B, Leriche A. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol 2001;39:107-113.
‹ previous next ›